PARP4

Across TCGA pan-cancer cohorts, PARP4 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PARP4 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PARP4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARP4 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

LSCC, GBM, and PDAC are the cancer types where PARP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.527	0.945	.005	35	view →
GBM	DFS	Tertile	All	0.687	0.959	<.001	16	view →
PDAC	OS	Median	IV	0.381	0.951	.006	12	view →
CCRCC	DFS	Quartile	III,IV	0.608	1.000	.017	11	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	6	view →
HNSC	DFS	Median	II,III,IV	0.901	0.989	.006	4	view →
UCEC	OS	Median	All	1.000	0.906	.009	4	view →
LUAD	OS	Median	III,IV	0.757	0.349	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PARP4–LSCC (DFS)

Open the LSCC breakdown →